Biologics/Immunotherapy News

Hematological laboratory and clinical chemical parameters determined that different allergen-specific immunotherapies did not lead to abnormal changes in basic immunological and metabolic processes, according to study results.

Recent data suggest that subcutaneous or sublingual immunotherapy may be an underused option that could benefit patients who are unable to manage their allergic rhinitis symptoms with oral and intranasal antihistamines, decongestants, and corticosteroid nasal sprays.

Standard quality house dust mite sublingual immunotherapy tablets maintained asthma control while reducing the need for inhaled corticosteroids in patients aged 14 years or older, according to recently published data.

Component-resolved diagnoses among children with pollen-related allergic rhinitis modified clinical decisions to prescribe specific immunotherapies, according to data recently published in the Journal of Allergy and Clinical Immunology.

House dust mite sublingual immunotherapy tablets were an effective treatment for children and adolescents with rhinitis and/or asthma due to house dust mite allergens, according to a recent study.

Researchers now suggest that the efficacy of grass pollen sublingual immunotherapy can be assessed by way of exhaled breath temperature, according to a recent study.

Venom immunotherapy has been cited as the best treatment option for patients allergic to stinging insects in a recent paper in the New England Journal of Medicine.

The FDA has approved the third sublingual immunotherapy tablet this month, according to a press release.

Healio.com recently reported on the clinical implications of sublingual immunotherapy based on two recent FDA approvals for SLIT agents indicated for grass pollen allergies; recent clinical trials published in the journals, and data presented at the American Academy of Allergy, Asthma & Immunology annual meeting in San Diego.

The FDA has approved the second sublingual immunotherapy agent in 2 weeks, according to a press release. Grastek (Timothy Grass Pollen Allergen Extract, Merck) sublingual immunotherapy (SLIT) tablets are indicated for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in patients aged 5 to 65 years.